Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
NDI-101150 inhibits hematopoietic progenitor kinase 1 (Hpk1), which may prevent immunosuppression in the tumor microenvironment and result in the induction of a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Thesaurus).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|NDI-101150 + Pembrolizumab||NDI-101150 Pembrolizumab||0||1|